PALIPERIDONE TEVA 150 mg, suspension for injection with extended release syringe
Active ingredients: PALIPÉRIDONE, Paliperidone palmitate
Commercialized according to BDPMANSM noticeDispensing in France: Prescription only
Suspension for injection with extended releasesyringeintramusculaire
Supply disruption
Package details
Original BDPM fields are shown in French.
- Official name
- PALIPERIDONE TEVA 150 mg, suspension injectable à libération prolongée
- Pharmaceutical form
- suspension injectable à libération prolongée
- Route of administration
- intramusculaire
- Presentation description
- 1 seringue préremplie polycyclooléfine avec 2 aiguilles
- Marketing authorisation holder
- TEVA (PAYS-BAS)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 7 Nov 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a specialist
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68516735CIP73023280CIP133400930232804Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| PALIPÉRIDONEsuspension | 150 mg · une seringue préremplie | FT |
| PALMITATE DE PALIPÉRIDONEsuspension | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.